Abstract
Objective HYROX is a rapidly growing hybrid fitness competition combining running with functional exercise stations. Our objective was to describe the 12-month prevalence, characteristics and severity of self-reported HYROX-related injuries.
Methods We conducted an international cross-sectional online survey of 418 HYROX athletes. The primary outcome was the self-reported 12-month period prevalence of at least one HYROX-related injury; secondary outcomes included an exposure-adjusted lower-bound rate per 1000 hours of total training exposure and the profile and severity of the most significant injury. Associated factors were examined by multivariable logistic regression.
Results Overall, 208 of 418 participants (49.8%, 95% CI 45.0 to 54.5) reported at least one HYROX-related injury. The exposure-adjusted lower-bound rate was 1.65 reported injuries per 1000 hours of total training exposure. Injuries mainly affected the lower extremity, most commonly the knee (20.8%); tendon-related complaints were the leading type (41.6%) and most were of gradual onset. Among participants with severity data, 20.3% reported more than 28 days of training interruption or no return to their previous performance level. Higher HYROX-specific training frequency was the only factor independently associated with injury reporting (adjusted OR 1.61, 95% CI 1.20 to 2.16; p = 0.001).
Conclusion Approximately half of respondents reported at least one HYROX-related injury during the preceding 12 months, predominantly involving gradual-onset lower-extremity complaints. Higher HYROX-specific training frequency was associated with injury reporting, although the cross-sectional design precludes causal interpretation. Prospective, exposure-based surveillance is needed to quantify HYROX-specific injury incidence and burden and examine whether training frequency, load distribution and recovery contribute to injury risk.
What is already known on this topic HYROX has expanded rapidly as a hybrid-fitness competition format, yet sport- specific injury evidence is limited to a single small cross-sectional study and exposure-adjusted estimates are lacking.
What this study adds Among 418 athletes, self-reported HYROX-related injuries over the preceding 12 months were common (period prevalence 49.8%) and predominantly gradual-onset, lower-extremity and tendon-related. Higher HYROX-specific training frequency was the only measured factor independently associated with injury reporting.
How this study might affect research, practice or policy These hypothesis-generating benchmarks make the case for prospective, exposure- based HYROX injury surveillance; they do not support specific training prescriptions, but identify training frequency, load distribution and recovery as priorities for future study. HYROX’s fixed, reproducible race structure offers a practical real-world model for such research.
Competing Interest Statement
The authors have declared no competing interest.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Ethics Committee of the Technical University of Munich (2026-32-S-CT; 3 February 2026) and conducted in accordance with the Declaration of Helsinki. Participation was voluntary and uncompensated; all participants provided electronic informed consent before completing the anonymous questionnaire. The participant information and consent text are provided in the online supplementary material.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability statement
Anonymised participant-level data are not publicly available because participants consented to analysis and publication of results, not to public deposition of the dataset. Data may be available from the corresponding author on reasonable request, subject to institutional approval.
